Attenuation  ||| S:0 E:12 ||| NNP
of  ||| S:12 E:15 ||| IN
Tubular  ||| S:15 E:23 ||| NNP
Injury  ||| S:23 E:30 ||| NNP
and  ||| S:30 E:34 ||| CC
Renal  ||| S:34 E:40 ||| NNP
Fibrosis  ||| S:40 E:49 ||| NNP
by  ||| S:49 E:52 ||| IN
TI-HU-YIN  ||| S:52 E:62 ||| JJ
via  ||| S:62 E:66 ||| IN
Reduction  ||| S:66 E:76 ||| NN
in  ||| S:76 E:79 ||| IN
Transforming  ||| S:79 E:92 ||| NNP
Growth  ||| S:92 E:99 ||| NNP
Factor-β1  ||| S:99 E:109 ||| NNP
Expression  ||| S:109 E:120 ||| NNP
in  ||| S:120 E:123 ||| IN
Unilateral  ||| S:123 E:134 ||| NNP
Ureteral  ||| S:134 E:143 ||| NNP
Obstruction  ||| S:143 E:155 ||| NNP
Mice  ||| S:155 E:160 ||| NNP
TI-HU-YIN  ||| S:160 E:170 ||| NNP
( ||| S:170 E:171 ||| -LRB-
JCKD ||| S:171 E:175 ||| NNP
) ||| S:175 E:176 ||| -RRB-
,  ||| S:176 E:178 ||| ,
a  ||| S:178 E:180 ||| DT
compound  ||| S:180 E:189 ||| NN
composed  ||| S:189 E:198 ||| VBN
of  ||| S:198 E:201 ||| IN
many  ||| S:201 E:206 ||| JJ
Chinese  ||| S:206 E:214 ||| JJ
herbs ||| S:214 E:219 ||| NN
,  ||| S:219 E:221 ||| ,
is  ||| S:221 E:224 ||| VBZ
hypothesized  ||| S:224 E:237 ||| VBN
to  ||| S:237 E:240 ||| TO
attenuate  ||| S:240 E:250 ||| VB
renal  ||| S:250 E:256 ||| JJ
tubular  ||| S:256 E:264 ||| JJ
injury  ||| S:264 E:271 ||| NN
and  ||| S:271 E:275 ||| CC
interstitial  ||| S:275 E:288 ||| JJ
fibrosis ||| S:288 E:296 ||| NN
.  ||| S:296 E:298 ||| .
Moreover ||| S:298 E:306 ||| RB
,  ||| S:306 E:308 ||| ,
its  ||| S:308 E:312 ||| PRP$
renoprotective  ||| S:312 E:327 ||| JJ
effects  ||| S:327 E:335 ||| NNS
were  ||| S:335 E:340 ||| VBD
assessed  ||| S:340 E:349 ||| VBN
in  ||| S:349 E:352 ||| IN
animal  ||| S:352 E:359 ||| NN
and  ||| S:359 E:363 ||| CC
in  ||| S:363 E:366 ||| IN
vitro  ||| S:366 E:372 ||| JJ
studies ||| S:372 E:379 ||| NNS
.  ||| S:379 E:381 ||| .
First ||| S:381 E:386 ||| NNP
,  ||| S:386 E:388 ||| ,
male  ||| S:388 E:393 ||| JJ
C57BL ||| S:393 E:398 ||| CD
/ ||| S:398 E:399 ||| CD
6  ||| S:399 E:401 ||| CD
mice  ||| S:401 E:406 ||| NNS
were  ||| S:406 E:411 ||| VBD
under  ||| S:411 E:417 ||| IN
sham  ||| S:417 E:422 ||| JJ
operation  ||| S:422 E:432 ||| NN
or  ||| S:432 E:435 ||| CC
unilateral  ||| S:435 E:446 ||| JJ
ureteral  ||| S:446 E:455 ||| JJ
obstruction  ||| S:455 E:467 ||| NN
( ||| S:467 E:468 ||| -LRB-
UUO ||| S:468 E:471 ||| NNP
)  ||| S:471 E:473 ||| -RRB-
surgery ||| S:473 E:480 ||| NN
,  ||| S:480 E:482 ||| ,
and  ||| S:482 E:486 ||| CC
then  ||| S:486 E:491 ||| RB
treated  ||| S:491 E:499 ||| VBN
with  ||| S:499 E:504 ||| IN
phosphate  ||| S:504 E:514 ||| JJ
buffer  ||| S:514 E:521 ||| NN
solution  ||| S:521 E:530 ||| NN
( ||| S:530 E:531 ||| -LRB-
PBS ||| S:531 E:534 ||| NNP
) ||| S:534 E:535 ||| -RRB-
,  ||| S:535 E:537 ||| ,
aliskirin  ||| S:537 E:547 ||| NN
and  ||| S:547 E:551 ||| CC
valsartan  ||| S:551 E:561 ||| NNS
( ||| S:561 E:562 ||| -LRB-
A+V ||| S:562 E:565 ||| NNP
) ||| S:565 E:566 ||| -RRB-
,  ||| S:566 E:568 ||| ,
and  ||| S:568 E:572 ||| CC
JCKD  ||| S:572 E:577 ||| NNP
for  ||| S:577 E:581 ||| IN
14  ||| S:581 E:584 ||| CD
days ||| S:584 E:588 ||| NNS
.  ||| S:588 E:590 ||| .
At  ||| S:590 E:593 ||| IN
7  ||| S:593 E:595 ||| CD
and  ||| S:595 E:599 ||| CC
14  ||| S:599 E:602 ||| CD
days ||| S:602 E:606 ||| NNS
,  ||| S:606 E:608 ||| ,
mice  ||| S:608 E:613 ||| NNS
were  ||| S:613 E:618 ||| VBD
sacrificed  ||| S:618 E:629 ||| JJ
and  ||| S:629 E:633 ||| CC
the  ||| S:633 E:637 ||| DT
kidney  ||| S:637 E:644 ||| NN
tissues  ||| S:644 E:652 ||| NNS
were  ||| S:652 E:657 ||| VBD
assessed  ||| S:657 E:666 ||| VBN
for  ||| S:666 E:670 ||| IN
histopathological  ||| S:670 E:688 ||| JJ
changes  ||| S:688 E:696 ||| NNS
and  ||| S:696 E:700 ||| CC
transforming  ||| S:700 E:713 ||| JJ
growth  ||| S:713 E:720 ||| NN
factor  ||| S:720 E:727 ||| NN
( ||| S:727 E:728 ||| -LRB-
TGF ||| S:728 E:731 ||| NNP
) ||| S:731 E:732 ||| -RRB-
-β1  ||| S:732 E:736 ||| CD
expression ||| S:736 E:746 ||| NN
.  ||| S:746 E:748 ||| .
As  ||| S:748 E:751 ||| RB
compared  ||| S:751 E:760 ||| VBN
to  ||| S:760 E:763 ||| TO
sham  ||| S:763 E:768 ||| VB
group ||| S:768 E:773 ||| NN
,  ||| S:773 E:775 ||| ,
UUO-PBS  ||| S:775 E:783 ||| JJ
group  ||| S:783 E:789 ||| NN
had  ||| S:789 E:793 ||| VBD
more  ||| S:793 E:798 ||| RBR
serious  ||| S:798 E:806 ||| JJ
tubular  ||| S:806 E:814 ||| JJ
dilatation  ||| S:814 E:825 ||| NN
and  ||| S:825 E:829 ||| CC
injury ||| S:829 E:835 ||| NN
,  ||| S:835 E:837 ||| ,
α-smooth  ||| S:837 E:846 ||| JJ
muscle  ||| S:846 E:853 ||| NN
actin-positive  ||| S:853 E:868 ||| JJ
areas ||| S:868 E:873 ||| NNS
,  ||| S:873 E:875 ||| ,
F4 ||| S:875 E:877 ||| CD
/ ||| S:877 E:878 ||| CD
80-positive  ||| S:878 E:890 ||| CD
macrophages ||| S:890 E:901 ||| NN
,  ||| S:901 E:903 ||| ,
and  ||| S:903 E:907 ||| CC
interstitial  ||| S:907 E:920 ||| JJ
fibrosis ||| S:920 E:928 ||| NN
.  ||| S:928 E:930 ||| .
Impressively ||| S:930 E:942 ||| NNP
,  ||| S:942 E:944 ||| ,
these  ||| S:944 E:950 ||| DT
pathologic  ||| S:950 E:961 ||| JJ
changes  ||| S:961 E:969 ||| NNS
were  ||| S:969 E:974 ||| VBD
significantly  ||| S:974 E:988 ||| RB
attenuated  ||| S:988 E:999 ||| VBN
in  ||| S:999 E:1002 ||| IN
UUO  ||| S:1002 E:1006 ||| NNP
mice  ||| S:1006 E:1011 ||| NNS
both  ||| S:1011 E:1016 ||| CC
treated  ||| S:1016 E:1024 ||| VBN
with  ||| S:1024 E:1029 ||| IN
JCKD  ||| S:1029 E:1034 ||| NNP
and  ||| S:1034 E:1038 ||| CC
A+V  ||| S:1038 E:1042 ||| NNP
as  ||| S:1042 E:1045 ||| RB
compared  ||| S:1045 E:1054 ||| VBN
to  ||| S:1054 E:1057 ||| TO
UUO-PBS  ||| S:1057 E:1065 ||| JJ
group ||| S:1065 E:1070 ||| NN
.  ||| S:1070 E:1072 ||| .
At  ||| S:1072 E:1075 ||| IN
14  ||| S:1075 E:1078 ||| CD
days ||| S:1078 E:1082 ||| NNS
,  ||| S:1082 E:1084 ||| ,
TGF-β1  ||| S:1084 E:1091 ||| CD
expression  ||| S:1091 E:1102 ||| NN
was  ||| S:1102 E:1106 ||| VBD
significantly  ||| S:1106 E:1120 ||| RB
suppressed  ||| S:1120 E:1131 ||| VBN
in  ||| S:1131 E:1134 ||| IN
kidney  ||| S:1134 E:1141 ||| NN
tissues  ||| S:1141 E:1149 ||| NNS
of  ||| S:1149 E:1152 ||| IN
UUO-JCKD  ||| S:1152 E:1161 ||| JJ
group  ||| S:1161 E:1167 ||| NN
as  ||| S:1167 E:1170 ||| IN
well  ||| S:1170 E:1175 ||| RB
as  ||| S:1175 E:1178 ||| RB
in  ||| S:1178 E:1181 ||| IN
UUO-A+V  ||| S:1181 E:1189 ||| CD
group ||| S:1189 E:1194 ||| NN
.  ||| S:1194 E:1196 ||| .
Second ||| S:1196 E:1202 ||| LS
,  ||| S:1202 E:1204 ||| ,
TGF-β1  ||| S:1204 E:1211 ||| CD
production  ||| S:1211 E:1222 ||| NN
was  ||| S:1222 E:1226 ||| VBD
increased  ||| S:1226 E:1236 ||| VBN
in  ||| S:1236 E:1239 ||| IN
macrophage  ||| S:1239 E:1250 ||| CD
J774  ||| S:1250 E:1255 ||| CD
cells  ||| S:1255 E:1261 ||| NNS
and  ||| S:1261 E:1265 ||| CC
NRK-52E  ||| S:1265 E:1273 ||| CD
proximal  ||| S:1273 E:1282 ||| CD
tubular  ||| S:1282 E:1290 ||| JJ
cells  ||| S:1290 E:1296 ||| NNS
stimulated  ||| S:1296 E:1307 ||| VBN
by  ||| S:1307 E:1310 ||| IN
angiotensin  ||| S:1310 E:1322 ||| NNS
( ||| S:1322 E:1323 ||| -LRB-
Ang ||| S:1323 E:1326 ||| NNP
) ||| S:1326 E:1327 ||| -RRB-
-II  ||| S:1327 E:1331 ||| JJ
at  ||| S:1331 E:1334 ||| IN
10  ||| S:1334 E:1337 ||| CD
nM  ||| S:1337 E:1340 ||| NN
for  ||| S:1340 E:1344 ||| IN
24  ||| S:1344 E:1347 ||| CD
h  ||| S:1347 E:1349 ||| NNS
and  ||| S:1349 E:1353 ||| CC
at  ||| S:1353 E:1356 ||| IN
1  ||| S:1356 E:1358 ||| CD
nM  ||| S:1358 E:1361 ||| NN
for  ||| S:1361 E:1365 ||| IN
48  ||| S:1365 E:1368 ||| CD
h ||| S:1368 E:1369 ||| NN
,  ||| S:1369 E:1371 ||| ,
respectively ||| S:1371 E:1383 ||| RB
.  ||| S:1383 E:1385 ||| .
JCKD  ||| S:1385 E:1390 ||| NNP
( ||| S:1390 E:1391 ||| -LRB-
≥  ||| S:1391 E:1393 ||| CD
400  ||| S:1393 E:1397 ||| CD
μg ||| S:1397 E:1399 ||| CD
/ ||| S:1399 E:1400 ||| CD
ml ||| S:1400 E:1402 ||| CD
)  ||| S:1402 E:1404 ||| -RRB-
inhibited  ||| S:1404 E:1414 ||| VBD
the  ||| S:1414 E:1418 ||| DT
TGF-β1  ||| S:1418 E:1425 ||| JJ
production  ||| S:1425 E:1436 ||| NN
at  ||| S:1436 E:1439 ||| IN
baseline  ||| S:1439 E:1448 ||| NN
and  ||| S:1448 E:1452 ||| CC
stimulated  ||| S:1452 E:1463 ||| VBN
by  ||| S:1463 E:1466 ||| IN
Ang  ||| S:1466 E:1470 ||| NNP
II  ||| S:1470 E:1473 ||| NNP
in  ||| S:1473 E:1476 ||| IN
both  ||| S:1476 E:1481 ||| DT
cell  ||| S:1481 E:1486 ||| NN
lines ||| S:1486 E:1491 ||| NNS
.  ||| S:1491 E:1493 ||| .
Our  ||| S:1493 E:1497 ||| PRP$
study  ||| S:1497 E:1503 ||| NN
showed  ||| S:1503 E:1510 ||| VBD
that  ||| S:1510 E:1515 ||| IN
JCKD  ||| S:1515 E:1520 ||| NNP
reduced  ||| S:1520 E:1528 ||| VBD
renal  ||| S:1528 E:1534 ||| JJ
injury ||| S:1534 E:1540 ||| NN
,  ||| S:1540 E:1542 ||| ,
macrophage  ||| S:1542 E:1553 ||| JJ
infiltration  ||| S:1553 E:1566 ||| NN
and  ||| S:1566 E:1570 ||| CC
interstitial  ||| S:1570 E:1583 ||| JJ
fibrosis  ||| S:1583 E:1592 ||| NNS
possibly  ||| S:1592 E:1601 ||| RB
through  ||| S:1601 E:1609 ||| IN
suppressing  ||| S:1609 E:1621 ||| VBG
the  ||| S:1621 E:1625 ||| DT
TGF-β1  ||| S:1625 E:1632 ||| JJ
expression  ||| S:1632 E:1643 ||| NN
in  ||| S:1643 E:1646 ||| IN
UUO  ||| S:1646 E:1650 ||| NNP
mice ||| S:1650 E:1654 ||| NNS
.  ||| S:1654 E:1656 ||| .
Accordingly ||| S:1656 E:1667 ||| RB
,  ||| S:1667 E:1669 ||| ,
JCKD  ||| S:1669 E:1674 ||| NNP
is  ||| S:1674 E:1677 ||| VBZ
potential  ||| S:1677 E:1687 ||| JJ
to  ||| S:1687 E:1690 ||| TO
retard  ||| S:1690 E:1697 ||| VB
the  ||| S:1697 E:1701 ||| DT
progression  ||| S:1701 E:1713 ||| NN
of  ||| S:1713 E:1716 ||| IN
chronic  ||| S:1716 E:1724 ||| JJ
kidney  ||| S:1724 E:1731 ||| NN
disease ||| S:1731 E:1738 ||| NN
.  ||| S:1738 E:1740 ||| .
Further  ||| S:1740 E:1748 ||| JJ
studies  ||| S:1748 E:1756 ||| NNS
are  ||| S:1756 E:1760 ||| VBP
needed  ||| S:1760 E:1767 ||| VBN
to  ||| S:1767 E:1770 ||| TO
validate  ||| S:1770 E:1779 ||| VB
its  ||| S:1779 E:1783 ||| PRP$
renoprotective  ||| S:1783 E:1798 ||| JJ
effects  ||| S:1798 E:1806 ||| NNS
in  ||| S:1806 E:1809 ||| IN
the  ||| S:1809 E:1813 ||| DT
inhibition  ||| S:1813 E:1824 ||| NN
of  ||| S:1824 E:1827 ||| IN
TGF-β1  ||| S:1827 E:1834 ||| CD
expression  ||| S:1834 E:1845 ||| NN
and  ||| S:1845 E:1849 ||| CC
the  ||| S:1849 E:1853 ||| DT
amelioration  ||| S:1853 E:1866 ||| NN
of  ||| S:1866 E:1869 ||| IN
renal  ||| S:1869 E:1875 ||| JJ
fibrosis ||| S:1875 E:1883 ||| NN
.  ||| S:1883 E:1885 ||| .
